Published in Clin J Am Soc Nephrol on February 25, 2016
Desensitization protocols for prospective pediatric renal transplant recipients. Pediatr Nephrol (2016) 0.75
Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med (2011) 6.72
Significance of the positive crossmatch test in kidney transplantation. N Engl J Med (1969) 5.50
Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med (2008) 4.32
Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol (2010) 2.66
A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant (2006) 2.37
Calculated PRA (CPRA): the new measure of sensitization for transplant candidates. Am J Transplant (2009) 2.21
OPTN/SRTR 2012 Annual Data Report: kidney. Am J Transplant (2014) 2.01
Quantifying the risk of incompatible kidney transplantation: a multicenter study. Am J Transplant (2014) 2.00
Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant (2011) 1.98
New national allocation policy for deceased donor kidneys in the United States and possible effect on patient outcomes. J Am Soc Nephrol (2014) 1.98
Renal transplantation across HLA and ABO antibody barriers: integrating paired donation into desensitization protocols. Am J Transplant (2010) 1.96
Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients. Transplantation (2012) 1.93
Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation (2010) 1.83
Infusion of high-dose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients. Transplantation (2012) 1.78
Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year. Am J Transplant (2015) 1.61
Independent of nephrectomy, weaning immunosuppression leads to late sensitization after kidney transplant failure. Transplantation (2012) 1.48
Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation (2009) 1.47
Donor-specific antibodies after ceasing immunosuppressive therapy, with or without an allograft nephrectomy. Clin J Am Soc Nephrol (2012) 1.46
Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant (2012) 1.31
Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant (2003) 1.29
Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. J Am Soc Nephrol (2001) 1.26
Calculated PRA: initial results show benefits for sensitized patients and a reduction in positive crossmatches. Am J Transplant (2010) 1.24
Desensitization protocols and their outcome. Clin J Am Soc Nephrol (2011) 1.21
Pathologic features of acute renal allograft rejection associated with donor-specific antibody, Analysis using the Banff grading schema. Transplantation (1996) 1.12
Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab. Transplantation (2013) 1.09
IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury. J Am Soc Nephrol (2015) 1.07
Evolution of HLA antibody detection: technology emulating biology. Immunol Res (2004) 1.05
Utility of HLA Antibody Testing in Kidney Transplantation. J Am Soc Nephrol (2015) 0.93
HLA antibody detection with solid phase assays: great expectations or expectations too great? Am J Transplant (2014) 0.92
Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience. Transplantation (2009) 0.91
The calculated panel reactive antibody policy: an advancement improving organ allocation. Curr Opin Organ Transplant (2011) 0.89
Limitations of rituximab/IVIg desensitization protocol in kidney transplantation; is this better than a tincture of time? Ann Transplant (2011) 0.86
HLA epitopes as viewed by antibodies: what is it all about? Am J Transplant (2015) 0.84
Differential effect of bortezomib on HLA class I and class II antibody. Transplantation (2014) 0.82
Clinical relevance of anti-HLA donor-specific antibodies detected by Luminex assay in the development of rejection after renal transplantation. Transplantation (2012) 0.81
The occurrence of cytotoxic and non-complement-fixing antibodies in the crossmatch serum of patients with early acute rejection episodes. Transplantation (1992) 0.80
The role of therapeutic apheresis in high immunologic risk renal transplantation: a review of current trends. Semin Dial (2012) 0.78
Fever, infection, and rejection after kidney transplant failure. Transplantation (2014) 0.78
Highly successful living donor kidney transplantation after conversion to negative of a previously positive flow-cytometry cross-match by pretransplant plasmapheresis. Transplant Proc (2005) 0.77